PD-1和LAG-3是表达在T细胞表面的抑制性受体,针对PD-1和LAG-3的抗体已经成为癌症治疗的重要组成部分,它们通过激活受体抑制T细胞增殖、细胞因子的产生和细胞毒性活性,进而通过促进对肿瘤的免疫反应来抑制肿瘤发展。 2024年8月发表在cel...
PD-1在肿瘤细胞上表达,通过与其配体MHC-II结合,抑制T细胞的活化和增殖,从而帮助肿瘤逃避免疫监视和攻击。LAG-3PD-1、LAG-3与肿瘤的关系02PD-1、LAG-3在弥漫性大B细胞淋巴瘤患者CD8+T细胞上的表达010203弥漫性大B细胞淋巴瘤患者CD8+T细胞上PD-1和LAG-3的表达模式存在差异。PD-1主要在肿瘤浸润淋巴细胞(TILs)...
目的:探讨慢性乙型肝炎患者(CHB)外周血CD8+T淋巴细胞耗竭分子PD-1,LAG-3,CD244,CD160的表达水平及其与治疗疗效的相关性.方法:采用流式细胞术方法分别检测74例CHB初治患者和20例正常健康人外周血CD8+T淋巴细胞PD-1,LAG-3,CD244,CD160的表达水平,同时在治疗前(T1)及治疗后24周(T2)及52周(T3)时随访接受...
肺腺癌中LAG-3,FGL1,PD-L1和CD8~+ T细胞表达的相关性研究 目的:LAG-3/FGL1通路在肿瘤的免疫逃逸中发挥了重要作用,是非小细胞肺癌免疫治疗研究热点,其在组织中的表达与PD-1/PD-L1的表达可能存在相关性,本研究旨在探索肺腺癌组... 朱菊明 - 《新疆医科大学》 被引量: 0发表: 2022年 Coadministration of ...
Lymphocyte Activation Gene-3 (LAG-3) is a transmembrane protein that binds MHC class II, enhances regulatory T cell activity, and negatively regulates cellular proliferation, activation, and homeostasis of T cells. Programmed Death 1 (PD-1) also negatively regulates T cell function. LAG-3 and ...
摘要: CD8+Tcells deficient in both PD-1 and LAG-3 exhibit altered exhaustion profiles and enhanced anti-tumor immunity driven by an autocrine IFN-γ-dependent mechanism. 展开 关键词: Keywordsimmune checkpoint inhibitormelanomaanti-tumor immunityimmunotherapyanti-PD-1anti-LAG-3immuno-oncologyCD8+T ...
之前观察到的细胞因子谱表明了Pegilodecali治疗的病人中CD8+ T细胞被活化,研究人员通过分析血液中的CD8+和CD4+ T细胞来进一步验证这一假说。先前报导在启动后T细胞上表达的免疫检查点,如PD-1、LAG-3和TIM-3表达会升高,另外从患者肿瘤组织或者血液分离的免疫检查点表达升高的CD8+体细胞中包含的识别肿瘤抗原的T细胞...
In contrast, during chronic infection, PD-1, LAG-3, and 2B4 remained highly expressed, and especially for PD-1 and 2B4, the expression increased on virus-specific CD8+ T cells after day 8 (Figures 4A and 4B). Thus, expression of inhibitory receptors is not unique to chronic viral ...
Fibrinogen-like protein 1 (FGL1)—Lymphocyte activating gene 3 (LAG-3) pathway is a promising immunotherapeutic target and has synergistic effect with programmed death 1 (PD-1)/programmed death ligand 1 (PD-L1). However, the prognostic significance of FG